In addition, the trend that patients with baseline NUT carcinoma experienced clinical benefit is consistent with antitumor activity found among patients with NUT carcinoma treated with the BET inhibitors molibresib, birabresib, and OTX015 [18,23], which may be indicative of altered BET inhibitor interactions with BRD3-NUT, BRD4-NUT, or NSD3-NUT fusions. The gene discussed is NSD3; the disease is nut midline carcinoma.